Hospital consolidation's regulatory obstacle course

Hospital systems weighing acquisitions face a calculation that would have seemed unthinkable a decade ago: the promised efficiency gains materialize only in limited circumstances, while antitrust regulators have grown so aggressive that four major merger attempts collapsed between 2022 and 2024. The decision to consolidate has become less about operational strategy and more about navigating multiple regulatory agencies, each with competing interests and expanding enforcement authority.

American hospital markets are already highly concentrated. As of 2016, 90 percent of U.S. metropolitan areas had highly concentrated hospital markets, with 19 percent of markets serving 11.2 million patients operated by a single hospital system. This concentration shapes how regulators evaluate any new consolidation.

Market concentration and the enforcement wave

The Hackensack Meridian-Englewood case illustrates how regulators view consolidation. Hackensack Meridian operated a 16-hospital system with two facilities in Bergen County, New Jersey; Englewood Health was a standalone community hospital in the same county. The merger would have given the combined entity control of three of the six inpatient general acute care hospitals in Bergen County.

In March 2022, a federal appeals court upheld an injunction blocking the deal, finding the merger would "substantially impair competition." The court accepted the FTC's argument that the relevant geographic market was defined by all hospitals used by commercially insured patients residing in Bergen County, and that significant price increases would result. Hackensack Meridian abandoned the acquisition in April 2022, joining three other blocked mergers: RWJBarnabas-St. Peter's in New Jersey (June 2022), HCA-Steward in Utah (June 2022), and Lifespan-Care New England in Rhode Island (February 2022).

The efficiency promise and its limits

Hospitals pursuing mergers typically pitch efficiency gains as their primary defense. When an independent hospital first becomes part of a system, studies show the parent can reduce operating costs by 4 to 7 percent through optimized staffing, shared services, and administrative consolidation. That promise is now subject to rigorous scrutiny. When two system-owned hospitals merge with each other, evidence shows essentially zero consumer-facing efficiencies, since both organizations have already optimized independently.

Courts require detailed documentation that any claimed savings are merger-specific, meaning they could not be achieved through less anticompetitive means such as data-sharing agreements or joint purchasing arrangements. No defendant has successfully used an efficiencies defense to rebut a government case at the appellate level. When hospitals within five miles of each other merge—the type of deal regulators scrutinize most—efficiency gains are minimal at best. Electronic health record integration, frequently cited by consolidation advocates as requiring a full merger, could theoretically be achieved through data-sharing agreements without complete organizational integration.

Quality rarely improves despite merger claims

This record undermines hospital claims that consolidation drives quality gains. Expanded physician networks, increased nursing staff, and peer collaboration do not reliably translate to better outcomes in merged systems. Research shows no rigorous evidence supporting quality improvements following mergers, and some circumstantial evidence suggests quality declines.

Regulators increasingly reject quality claims as justification for consolidation that reduces local competition. The Hackensack court decision noted that "any benefits that would result from the merger did not offset anticompetitive concerns." This framing reverses the burden: hospitals must now prove not only that quality will improve, but that improvement will outweigh documented price increases and reduced competition.

Price increases dwarf any efficiency gains

The economic evidence on price impacts is unambiguous. The magnitude varies by deal structure. Six years after acquisition, cross-market hospital mergers increased acquirer prices by an average of 12.9 percent relative to control hospitals. Serial acquirers—systems making multiple acquisitions—saw even larger increases, at 16.3 percent. When the target hospital had greater market share than the acquirer, price increases reached 21.8 percent.

In concentrated markets, price escalation becomes severe. The Department of Health and Human Services found hospital care prices can rise 6 to 65 percent at merged medical centers. Mergers of hospitals within five miles of each other lead to average price increases of 6 percent. Monopoly hospitals—those with no nearby competitors—charge 12 percent higher prices than hospitals facing three or more competing systems. In already-concentrated markets, price increases of 20 to 30 percent are common, with some documented as high as 65 percent.

These price increases extend throughout healthcare systems. When hospitals acquire physician practices, service prices rise an average of 14 percent. Vertical integration effected price increases ranging from 4 to 16 percent depending on specialty, according to 2025 analysis by the Government Accountability Office.

How federal merger review works

Deals above $111 million—the Hart-Scott-Rodino threshold, adjusted annually—must be reported to the FTC and DOJ. The initial 30-day waiting period begins when both parties file, typically on the same day. If regulators find competitive concerns, they issue a second request for additional information, documents, and analysis. This second request phase can extend review for many additional months, requiring parties to produce millions of pages and provide detailed competitive analyses.

Hospital systems must demonstrate how their efficiency claims are merger-specific and likely to benefit consumers through lower prices rather than higher executive compensation or profits. Regulators now require hospitals to show that claimed efficiencies could not be achieved through joint ventures, shared services, or data-sharing agreements that stop short of full integration. Cost savings important to hospital management may not count in regulatory analysis, especially when a merger threatens local competition. The FTC's updated guidelines emphasize assessing the structure of local health care markets, with greater attention to concentrated hospital environments and the labor-market effects of mergers.

State alternatives face FTC skepticism

Under COPA laws—adopted in states including New York, North Carolina, and others—regulators can grant certificates providing "immunity from both federal antitrust action and private claims." This operates under "active supervision" by state health officials. New York's COPA framework requires state review of financial condition, competitive levels in the service area, difficulties recruiting healthcare professionals, and merger effects.

The SUNY Upstate-Crouse merger illustrates the process. The hospitals applied for a COPA in New York, but the FTC submitted a critical 57-page public comment predicting competitive harm. Faced with "operational and economic headwinds," the system abandoned the merger in February 2023. The FTC argues the COPA tradeoff fails to protect consumers. State health departments frequently lack resources to maintain rigorous oversight after mergers complete. Some states repealed COPA laws after decades of experience, including North Carolina and Maine, suggesting regulatory fatigue sets in.

In March 2025, this skepticism proved consequential. Union Hospital and Terre Haute Regional Hospital submitted a COPA application to the Indiana Department of Health in February 2025 after withdrawing their initial application in November 2024. The FTC staff voted 4-0 in March 2025 to submit comments opposing the merger, stating that "competition consistently results in better outcomes for patients and workers than consolidation subject to COPAs."

Wage suppression and labor market effects

Merged hospital systems exercise monopsony power in local labor markets, allowing them to negotiate lower wages with nurses and other clinicians possessing hospital-specific skills. This wage suppression becomes more severe in concentrated markets where workers have fewer alternative employers. Research distinguishes between specialized workers like nurses and physicians, where consolidation reduces wages, and less specialized workers, where wage effects remain minimal.

Expanding regulatory compliance beyond antitrust

Hospital systems navigating mergers now manage an expanding compliance universe beyond antitrust review. The FDA has approved more than 1,600 artificial intelligence-enabled medical devices as of early 2026, with 335 cleared in 2025. Merged systems must integrate disparate AI systems, manage FDA regulatory pathways for Class I and Class II devices through either 510(k) clearance or De Novo classification, and ensure bias audits for high-risk algorithms. New federal laws introduce mandatory bias audits to address disparities in diagnostics, with some requiring annual assessments of AI systems' impact on protected groups including race, age, and disability.

The FTC separately enforces rules against deceptive advertising and data collection practices. HHS oversees HIPAA compliance for any health information flowing through integrated systems. This multi-agency oversight means hospital merger teams must coordinate with compliance staff across multiple regulatory domains simultaneously, extending timelines and increasing costs.

How systems reassess consolidation today

Hospital boards now build merger analyses around regulatory risk in ways they did not before 2020. A proposed acquisition between two independent hospitals close to each other faces probable federal challenge. A deal between two already-merged systems faces skepticism about whether additional efficiency gains are real. COPA applications in certain states circumvent federal review but impose permanent rate restrictions and continued state oversight.

Systems that have abandoned merger plans consistently cite expected regulatory costs and low probability of success as primary reasons. Those still pursuing consolidation increasingly structure deals to show limited overlap—targeting hospitals in different geographic markets or those far enough apart to plausibly claim no competitive harm. The efficiency gains that made consolidation attractive grow harder to demonstrate as the most promising merger targets face the greatest regulatory barriers. Facing this environment, some hospital systems have shifted strategy from acquisition-driven growth to joint operating agreements, shared services arrangements, and regional referral networks that avoid the full consolidation triggering antitrust review.

Related coverage: What Antitrust Law Actually Prohibits.